Search
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalLumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.
Dirlotapide
go.drugbank.com/drugs/DB11399InvestigationalVet approvedIt is marketed by Pfizer and Zoetis under the brand name, _Slentrol_, and is not intended for human use.
Metampicillin
go.drugbank.com/drugs/DB13836ExperimentalMetampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin.
Doxylamine
go.drugbank.com/drugs/DB00366ApprovedInvestigationalVet approvedHistamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
Luspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigationalLuspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...
Categories: Phosphotransferases (Alcohol Group Acceptor)Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...
Safflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnSafflower (Carthamus tinctorius L) is a herbaceous plant in the Asteraceae family. Extracted from the seeds of safflowers, safflower oil is a rich source of various saturated fatty acids, monounsaturated fatty acid (oleic acid) or essent...
Antithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalIt is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.